Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Peptide Mimotope Candidates for Otitis Media Vaccine

Posted Jun 15 2010 5:00pm

Description of Invention:
This technology describes peptide mimotopes of lipooligosaccharides (LOS) from nontypeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis that are suitable for developing novel vaccines against the respective pathogens, for which there are currently no licensed vaccines. The mimotopes not only immunologically mimic LOSs from NTHi and M. catarrhalis but will also bind to antibodies specific for the respective LOS. NTHi and M. catarrhalis are common pathogens that cause otitis media in children and lower respiratory tract infections in adults. The effectiveness of a vaccine could be increased by substitution of a LOS epitope with a peptide mimic. Preliminary experiments have shown that some of the mimic peptides conjugated to a carrier were as effective as their respective LOS-based vaccine in stimulating a humoral immune response in rabbits. A single consensus amino acid sequence was identified for M. catarrhalis, while four such sequences were identified for NTHi. Thus, the identified peptides are promising candidates for developing novel vaccines for NTHi or M. catarrhalis.

Applications:
Otitis media vaccine

Development Status:
In vivo data available

Inventors:
Xin-xing Gu (NIDCD)


Patent Status:
HHS, Reference No. E-344-2002/0
US, , Patent No. 7,514,529, Issued 07 Apr 2009
PCT, Application No. PCT/US2004/001457 filed 21 Jan 2004


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The NIDCD Vaccine Research Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Peptide vaccines derived from LOS of NTHi or M. catarrhalis. Please contact Marianne Lynch, a technology development specialist, at 301-594-4094 or lynchm2@mail.nih.gov for more information.


Portfolios:
Infectious Diseases
Infectious Diseases - Vaccines
Rare Diseases
In-vivo Data



For Additional Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220


Ref No: 776

Updated: 06/2010

Post a comment
Write a comment:

Related Searches